Summary Serum p53 antibody levels were analysed using an enzyme-linked immunosorbent assay in serum samples obtained before surgery from 184 consecutive patients with primary colorectal cancer. Possible associations with tumour stage and tumour differentiation and the relation to patient survival time after a median follow-up of 6 years were studied. Analysis of serum p53 antibodies in the entire material demonstrated prognostic value in univariate analysis (P = 0.02); a finding that did not remain (P = 0.07) when the Dukes' stage was included in a multivariate analysis model. When the survival analysis was restricted to the potentially cured patients in Dukes' stages A-C, the serum p53 antibody levels retained independent prognostic value (P = 0.03). No clear association with tumour differentiation was found. We conclude that analysis of serum p53 antibodies may be of value for the identification of patients with different prognoses. This may be of relevance for selection of patients for adjuvant treatment.
Mutations or other changes in the p53 gene -the most frequent genetic alterations found in human malignancies (Levine et al, 1991; Harris and Hollstein, 1993) -can be detected in 40-70% of all colorectal adenocarcinomas (Hollstein et al, 1991; Vogelstein and Kinzler, 1992; Hamelin et al, 1994; Chang et al, 1995) . It has been reported that p53 mutations are associated with poor prognosis in colorectal cancer (Hamelin et al, 1994; Goh et al, 1995; Finkelstein et al, 1996; Smith et al, 1997) , while such a relation was not observed by Dix et al (1994a) . Overexpression of the p53 protein is detectable in 30-70% of the tumours using immunohistochemistry. In some studies (Remvikos et al, 1992; Sun et al, 1992; Auvinen et al, 1994; Bosari et al, 1994) p53 protein overexpression has been shown to correlate to patient survival, while this has not been confirmed in other studies (Bell et al, 1993; Baas et al, 1994; Dix et al, 1994a; Morrin et al, 1994; Mulder et al, 1995; Kressner et al, 1996 Poller et al, 1997) .
Mutant p53 protein, and other tumour-specific antigens, may be a target of the host's immune response (Schlichtholtz et al, 1992; Mudenda et al, 1994) . Studies have shown that 9-26% of patients with different carcinomas have mounted a humoral immune response (antibodies) to abnormal p53 protein (Caron de Fromental et al, 1987; Levine et al, 1991; Angelopoulou et al, 1994) . Thus, anti-p53 antibodies may be a serological marker for malignancy.
Recent studies have shown increased serum antibody levels against mutant p53 protein in patients with breast (Crawford et al, 1982; Davidoff et al, 1992; Schlichtholtz et al, 1992; Mudenda et al, 1994) , lung (Winter et al, 1992; Schlichtholtz et al, 1994 ) and colorectal cancer (Houbiers et al, 1995; Angelopoulou et al, 1997) . Two of the studies in breast cancer patients have indicated that the occurrence of p53 antibodies may be a useful determinant with regard to poor prognosis (Schlichtholtz et al, 1992; Mudenda et al, 1994) . This was also seen in the study on patients with colorectal cancer, but the prognostic information was limited to tumours in Dukes' stage A and Astler-Coller B1 (Houbiers et al, 1995) . The aim of this study was to evaluate whether the levels of p53 antibodies in serum samples, obtained before surgery from patients with colorectal cancer, are of importance for prediction of tumour stage and, thus, of potential value for selecting patients resected for cure to adjuvant treatment.
MATERIALS AND METHODS Patients
Serum samples were collected before surgery from 184 patients resected for colorectal cancer in Uppsala and Falun County during the years from January 1987 to November 1992. The age and sex distribution, Dukes' stage and tumour differentiation are given in Table 1 . One hundred and fifty-six patients (85%) were resected for cure. In the remaining 28 patients, distant metastases were detected peroperatively, and consequently they underwent a palliative resection. This group was classified as Dukes' stage D. At follow-up in October 1995, 82 (45%) patients had died from cancer or from other causes, but with known tumour burden.
Twenty-eight (15%) patients died from other causes without any indications of tumour relapse. No patient was lost at follow-up. The median survival time of the 74 living patients was 80 months (range 33-102). Routine biopsies from each tumour were taken for histopathological classification. The tumours were graded according to the WHO classification (Morson and Sobin, 1976) and staged according to the Dukes' classification system (Dukes and Bussey, 1958) . Immunohistochemical analysis of overexpression of p53 protein p53 protein overexpression was evaluated using an immunohistochemical method (Kressner et al, 1996) . Briefly, DO-7 monoclonal antibody was used in combination with biotinylated horse antimouse IgG antibody as secondary antibody, followed by avidin-biotin blocking kit and ethyl carbazole substrate. The sections were classified as negative or positive.
Statistical analyses
The Cox proportional hazards model was used in both the univariate and the multivariate survival analyses. Survival curves were constructed using the Kaplan-Meier method, and differences between curves were tested using the log-rank test (Peto et al, 1977 DO-7 (Kressner et al, 1996) . The association of tumours with p53 protein overexpression with increased serum p53 antibody levels was significant: 24 (45%) of 53 patients with tumours showing overexpression had high levels of serum p53 antibodies, while this was the case in only 6 (11% I) of 57 patients without p53 overexpression (P = 0.005).
p53 antibodies and prognosis
There was a significant relationship between serum p53 antibody status and cancer-specific survival time, with shorter survival time for those patients who had increased levels of p53 serum antibodies than for those without. This finding was observed both when the entire patient material was analysed (P = 0.02, log-rank test) and when the analysis was restricted to the potentially cured patients with tumours in Dukes' stages A-C (P = 0.03, log-rank test; Figure 1 ).
An analysis based on all four Dukes' stages, and with p53 antibody status categorized as shown in Table 2 , showed decreased survival with increased p53 antibody index in a univariate analysis. The relative hazards (RHs) were 1.55 (95% CI 0.78-3.07), 1.61 (0.85-3.04) and 1.98 (1.07-3.68). In a multivariate model adjusting for Dukes' stage, the significant effect of serum p53 levels disappeared, although the tendency that p53 antibody status was a risk factor remained (P = 0.07). The RHs were 1.77 (0.89-3.53), 1.74 (0.92-3.31) and 1.32 (0.70-2.49).
In the group of potentially cured patients, the prognostic value of p53 antibody status remained, however, even after adjustment for Dukes' stage (Table 2 ). The RH in the highest category was 2.2 (1.04-4.61). Further adjustments for a large number of variables had only marginal effects as regards the effect of p53. The RHs in the two highest categories remained at about 2, with P-values equal to 0.04 and 0.10.
DISCUSSION
The proportion of patients with detectable serum p53 antibodies (32%) is consistent with a previous report on colorectal cancer (Houbiers et al, 1995) , but represents a higher figure than that reported by Angelopoulou et al (1994) who found p53 antibodies in 16% of their patients.
We found that the p53 antibody status was not only a prognostic indicator in a univariate analysis but also an independent prognostic factor when analysed in a multivariate model regarding the subset of patients who were radically resected. The result is thus in contrast to Houbiers et al (1995) , who did not find an independent relation with prognosis in a multivariate analysis including the Dukes' stage but reported a weak association (P = 0.04) between high p53 serum levels and prognosis in patients with an early stage of the disease (Dukes' stage A).
Thus, detectable levels of p53 antibodies in serum seem to indicate more aggressive tumours in colorectal cancer. Studies in other tumour types support this notion (Crawford et al, 1982; Davidoff et al, 1992; Schlichtholtz et al, 1992; Winter et al, 1992; Mudenda et al, 1994) . Loss of the p53 gene suppressor function has previously been reported in a range of human malignancies (Hollstein et al, 1991; Levine et al, 1991; Chang et al, 1995) , including colorectal cancer (Levine et al, 1991; Remvikos et al, 1992; Sun et al, 1992; Vogelstein and Kinzler, 1992; Bell et al, 1993; Auvinen et al, 1994; Bosari et al, 1994; Dix et al, 1994a; Hamelin et al, 1994; Goh et al, 1995) . A mutation in the p53 gene results in an accumulation of mutant p53 protein or in an overproduction of normal wild-type p53 protein (Dix et al, 1994a and b) . Mutant p53 protein is more stable than the wild-type p53 protein (Bruner et al, 1993; Dix et al, 1994a and b) , and this seems to be necessary for the development of a humoral response with detectable levels of anti-p53 antibodies in the peripheral circulation (Crawford et al, 1982) .
In this study, and in concordance with Houbiers et al (1995), we were also able to demonstrate a significant association between overexpression of p53 in tumour sections with expression of serum p53 antibodies (P < 0.005), although increased levels were only British Journal of Cancer (1998) This implies that either the cut-off level is too high or that the development of antibodies is dependent upon the type of genetic change underlying the overexpression of p53 protein required for positive immunohistochemistry. Another point is that a p53 mutation does not always result in immunohistochemical detection of overexpression of p53 protein (Dix et al, 1994a; Houbiers et al, 1995; Kressner et al, manuscript submitted) Preoperatively increased serum tumour levels of CEA, TPA and other markers have been reported to provide prognostic information, but their clinical relevance is yet to be defined as they mainly identify patients with metastases already detectable at diagnosis (Lindmark et al, 1995) . Post-operatively, they may also provide additional prognostic information to that given by Dukes' stage, but the associations are then weaker, and thus the clinical relevance is also doubtful. In the present study, a significant effect of serum levels of p53 remained after adjustment for the preoperative level of serum CEA. The prognostic effect of CEA was, in this patient material, rather strong, although it did not retain its prognostic information in either of the multivariate models shown in Table 2 (data not shown).
If the presence of serum p53 antibodies, available before surgery, is a marker of poor prognosis, which our study suggests, it could be of value preoperatively for the selection of patients with colorectal cancer for additional treatment. It may also be useful in post-operative patient monitoring. This application has to be explored in further studies.
